Dr. Michael A. Singer, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Boston University School of Medicine (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 667
Licensed in Texas since 1995, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: Boston University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
TX license J8373 (first issued 1995; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Medical Center Ophthalmology Associates (12 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 667
- Services billed
- 45,920
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 21,533 | 95 |
| Imaging of retina | 1,054 | 403 |
| Injection of drug into eye | 741 | 183 |
| Established patient complete exam of visual system | 733 | 581 |
| Closure of tear duct opening using plug | 615 | 415 |
| Injection, aflibercept, 1 mg | 502 | 72 |
| Extended exam of the back part of the eye with retinal drawing | 450 | 370 |
| Photography of the retina | 345 | 266 |
| Established patient office or other outpatient visit, 20-29 minutes | 301 | 273 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 247 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Bromfenac Sodium | 45 |
| Latanoprost Other prescribers in San Antonio, TX | 27 |
| Xiidra (lifitegrast) Other prescribers in San Antonio, TX | 17 |
| Ketorolac Tromethamine Other prescribers in San Antonio, TX | 11 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in San Antonio, TX | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 132 payments worth $238,138 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $85,475 |
|---|---|
| Harrow Eye, LLC | $64,833 |
| Apellis Pharmaceuticals, Inc. | $40,187 |
| Ani Pharmaceuticals, Inc. | $20,529 |
| Astellas Pharma US Inc | $10,688 |
| AbbVie Inc. | $6,367 |
| Sun Pharmaceutical Industries Inc. | $5,977 |
| Genentech USA, Inc. | $3,211 |
| Compensation for services other than consulting (speaking, faculty) | $87,084 |
|---|---|
| Consulting Fee | $84,616 |
| Speaking at a medical education program | $32,865 |
| Honoraria | $18,963 |
| Travel and Lodging | $9,509 |
| Food and Beverage | $5,100 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Harrow Eye, LLC Jun 19, 2025 | Consulting Fee IHEEZO; TRIESENCE · OPTOMETRY | $13,256 |
| Harrow Eye, LLC Jul 25, 2025 | Consulting Fee IHEEZO; TRIESENCE · OPTOMETRY | $13,140 |
| Harrow Eye, LLC Jul 17, 2025 | Consulting Fee IHEEZO; TRIESENCE · OPTOMETRY | $12,995 |
| Harrow Eye, LLC May 1, 2025 | Consulting Fee IHEEZO; TRIESENCE · OPTOMETRY | $12,757 |
| Apellis Pharmaceuticals, Inc. Jan 22, 2025 | Speaking at a medical education program Syfovre · Ophthalmology | $11,403 |
| Apellis Pharmaceuticals, Inc. Sep 17, 2025 | Speaking at a medical education program Syfovre · Ophthalmology | $11,403 |
| Regeneron Healthcare Solutions, Inc. Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $11,050 |
| Regeneron Healthcare Solutions, Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $11,050 |
| Regeneron Healthcare Solutions, Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $11,050 |
| Regeneron Healthcare Solutions, Inc. Nov 4, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $11,050 |
All 61 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 15, 2025 | Consulting Fee OZURDEX · EYE CARE | $6,181 |
| Astellas Pharma US Inc Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $7,200 |
| Astellas Pharma US Inc Nov 13, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to McAllen, TX | $1,378 |
| Astellas Pharma US Inc Nov 13, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to McAllen, TX | $448 |
| Astellas Pharma US Inc Nov 13, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to McAllen, TX | $210 |
| Regeneron Healthcare Solutions, Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $11,050 |
| Regeneron Healthcare Solutions, Inc. Nov 5, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to SAN FRANCISCO, CA · in-kind | $555 |
| Regeneron Healthcare Solutions, Inc. Nov 4, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $11,050 |
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $2,476 |
| Regeneron Healthcare Solutions, Inc. Oct 23, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to PITTSBURGH, PA · in-kind | $402 |
| Regeneron Healthcare Solutions, Inc. Oct 23, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to SAN FRANCISCO, CA · in-kind | $347 |
| Regeneron Healthcare Solutions, Inc. Oct 23, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to SAN FRANCISCO, CA · in-kind | $322 |
| Ani Pharmaceuticals, Inc. Oct 16, 2025 | Honoraria PURIFIED CORTROPHIN GEL · Treatment of certain chronic autoimmune disorders including acute exacerbations | $5,550 |
| Ani Pharmaceuticals, Inc. Oct 16, 2025 | Travel and Lodging PURIFIED CORTROPHIN GEL · Treatment of certain chronic autoimmune disorders including acute exacerbations · travel to Mcallen, TX | $204 |
| Regeneron Healthcare Solutions, Inc. Oct 10, 2025 | Consulting Fee EYLEA HD · OPHTHALMOLOGY | $1,105 |
| Ani Pharmaceuticals, Inc. Oct 7, 2025 | Honoraria ILUVIEN · treatment of diabetic macular edema in patients who have been previously treated | $4,163 |
| Ani Pharmaceuticals, Inc. Oct 6, 2025 | Travel and Lodging PURIFIED CORTROPHIN GEL · Treatment of certain chronic autoimmune disorders including acute exacerbations · travel to Mcallen, TX · in-kind | $308 |
| Ani Pharmaceuticals, Inc. Oct 6, 2025 | Travel and Lodging PURIFIED CORTROPHIN GEL · Treatment of certain chronic autoimmune disorders including acute exacerbations · travel to Mcallen, TX · in-kind | $213 |
| Ani Pharmaceuticals, Inc. Oct 6, 2025 | Travel and Lodging PURIFIED CORTROPHIN GEL · Treatment of certain chronic autoimmune disorders including acute exacerbations · travel to Mcallen, TX · in-kind | $80.00 |
| Apellis Pharmaceuticals, Inc. Oct 1, 2025 | Speaking at a medical education program Syfovre · Ophthalmology | $1,500 |
| Apellis Pharmaceuticals, Inc. Oct 1, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Austin, TX | $143 |
| Regeneron Healthcare Solutions, Inc. Sep 23, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to PARAMUS, NJ · in-kind | $218 |
| Regeneron Healthcare Solutions, Inc. Sep 23, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to PARAMUS, NJ · in-kind | $133 |
| Apellis Pharmaceuticals, Inc. Sep 17, 2025 | Speaking at a medical education program Syfovre · Ophthalmology | $11,403 |
| Ani Pharmaceuticals, Inc. Sep 17, 2025 | Honoraria PURIFIED CORTROPHIN GEL · Treatment of certain chronic autoimmune disorders including acute exacerbations | $2,775 |
| Sun Pharmaceutical Industries Inc. Sep 12, 2025 | Consulting Fee | $5,400 |
| Sun Pharmaceutical Industries Inc. Sep 12, 2025 | Travel and Lodging travel to Punta Gorda, FL | $512 |
| Apellis Pharmaceuticals, Inc. Sep 8, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Rosemont, IL · in-kind | $304 |
| Apellis Pharmaceuticals, Inc. Sep 8, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Rosemont, IL · in-kind | $213 |
| Apellis Pharmaceuticals, Inc. Aug 27, 2025 | Speaking at a medical education program Syfovre · Ophthalmology | $7,059 |
| Apellis Pharmaceuticals, Inc. Aug 15, 2025 | Consulting Fee Syfovre · Ophthalmology | $4,344 |
| Ani Pharmaceuticals, Inc. Aug 7, 2025 | Honoraria ILUVIEN · treatment of diabetic macular edema in patients who have been previously treated | $6,475 |
| Harrow Eye, LLC Jul 25, 2025 | Consulting Fee IHEEZO; TRIESENCE · OPTOMETRY | $13,140 |
| Regeneron Healthcare Solutions, Inc. Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $8,840 |
| Harrow Eye, LLC Jul 17, 2025 | Consulting Fee IHEEZO; TRIESENCE · OPTOMETRY | $12,995 |
| Regeneron Healthcare Solutions, Inc. Jul 17, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to MCALLEN, TX · in-kind | $369 |
| Regeneron Healthcare Solutions, Inc. Jun 21, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to MCALLEN, TX · in-kind | $168 |
| Regeneron Healthcare Solutions, Inc. Jun 20, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $1,621 |
| Regeneron Healthcare Solutions, Inc. Jun 20, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to MCALLEN, TX · in-kind | $218 |
| Harrow Eye, LLC Jun 19, 2025 | Consulting Fee IHEEZO; TRIESENCE · OPTOMETRY | $13,256 |
| Astellas Pharma US Inc May 29, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $1,200 |
| Harrow Eye, LLC May 28, 2025 | Consulting Fee TRIESENCE · OPTOMETRY | $700 |
| Regeneron Healthcare Solutions, Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $11,050 |
| Regeneron Healthcare Solutions, Inc. May 13, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $10,498 |
| Harrow Eye, LLC May 9, 2025 | Consulting Fee TRIESENCE · OPTOMETRY | $2,800 |
| Regeneron Healthcare Solutions, Inc. May 7, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to AVENTURA, FL · in-kind | $374 |
| Harrow Eye, LLC May 1, 2025 | Consulting Fee IHEEZO; TRIESENCE · OPTOMETRY | $12,757 |
| Regeneron Healthcare Solutions, Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $11,050 |
| Regeneron Healthcare Solutions, Inc. Apr 8, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to PARAMUS, NJ · in-kind | $689 |
| Genentech USA, Inc. Apr 5, 2025 | Consulting Fee Vabysmo · Immunology and Ophthalmology | $2,995 |
| Apellis Pharmaceuticals, Inc. Mar 28, 2025 | Consulting Fee Syfovre · Ophthalmology | $543 |
| Apellis Pharmaceuticals, Inc. Mar 25, 2025 | Speaking at a medical education program Syfovre · Ophthalmology | $1,500 |
| Harrow Eye, LLC Feb 27, 2025 | Consulting Fee IHEEZO; TRIESENCE · OPTOMETRY | $5,600 |
| Regeneron Healthcare Solutions, Inc. Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $11,050 |
| Regeneron Healthcare Solutions, Inc. Feb 12, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to SARASOTA, FL · in-kind | $864 |
| Apellis Pharmaceuticals, Inc. Jan 22, 2025 | Speaking at a medical education program Syfovre · Ophthalmology | $11,403 |
| Harrow Eye, LLC Jan 20, 2025 | Consulting Fee IHEEZO; TRIESENCE · OPTOMETRY | $2,800 |
| Apellis Pharmaceuticals, Inc. Jan 16, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Salt Lake City, UT · in-kind | $498 |
| Apellis Pharmaceuticals, Inc. Jan 16, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Salt Lake City, UT · in-kind | $273 |
| Apellis Pharmaceuticals, Inc. Jan 16, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Salt Lake City, UT | $57.68 |
| Apellis Pharmaceuticals, Inc. Jan 16, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Salt Lake City, UT | $6.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $354,634 in research payments for these studies, mostly to the institutions running them.
- CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitre…
Boehringer Ingelheim International GmbH - Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. - Study of the port delivery system with ranibizumab in patients with diabetic macular edema
Genentech, Inc. - A Phase 1 SAD MD in Diabetic Macular Edema
Genentech, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Bayer HealthCare Pharmaceuticals Inc. - A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Sanofi US Services Inc. · Active, not recruiting · NCT06660667 - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - New Day Study
Ani Pharmaceuticals, Inc. - A phase iii multicenter observation comparator study of the efficacy safety and pharmacokinetics
Genentech, Inc. - Port Delivery System of Ranibizumab Extension Study
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.